<DOC>
	<DOCNO>NCT00381706</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving one chemotherapy drug ( combination chemotherapy ) together cetuximab may kill tumor cell . PURPOSE : This randomized phase II trial study three different combination chemotherapy regimens compare well work give together cetuximab treat patient metastatic esophageal cancer gastroesophageal junction cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Cetuximab Treating Patients With Metastatic Esophageal Cancer Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OUTLINE : This randomize , multicenter study . Patients stratify accord histology ( squamous cell carcinoma v adenocarcinoma ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( 0 1 v 2 ) . Patients randomize 1 3 treatment arm . For information please see `` Arms '' section include detailed description treatment regimen . The primary objective study evaluate tumor response rate ( RR ) regimens trial select promise regimen base RR test patient metastatic esophageal GE junction adenocarcinoma . The secondary objective : 1 . To evaluate overall survival ( OS ) regimens trial patient metastatic esophageal GE junction adenocarcinoma . 2 . To evaluate progression-free survival ( PFS ) regimens trial patient metastatic esophageal GE junction adenocarcinoma . 3 . To evaluate time treatment failure ( TTF ) regimens trial patient metastatic esophageal GE junction adenocarcinoma . 4 . To determine type severity toxicity associate regimen multi-institutional phase II setting . 5 . Quantitative immunohistochemistry result correlate objective response rate , overall survival time progression . 6 . To evaluate cellular damage ( apoptosis ) result oxaliplatin . 7 . To determine germline EGFR variant correlate skin rash patient treat cetuximab . 8 . To evaluate correlation exists germline EGFR variant tumor EFGR expression measure immunohistochemistry . All subject must premedicated diphenhydramine hydrochloride 50 mg IV ( similar agent ) prior first dose cetuximab effort minimize infusion hypersensitivity reaction . Premedication recommend prior subsequent dos , dose diphenhydramine ( similar agent ) may reduce investigator 's discretion . More information detail protocol include description premedication requirement . Patients closely monitor treatment-related adverse event . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Metastatic disease esophagus gastroesophageal junction 1 . Histologic , cytologic radiologic documentation metastatic squamous cell carcinoma adenocarcinoma esophagus gastroesophageal junction . Radiologic , endoscopic , histologic cytologic evidence locally recurrent locally residual ( postresection ) disease also permit . 2 . For purpose study , undifferentiated adenocarcinomas adenosquamous tumor consider adenocarcinomas . In addition , tumor involve gastroesophageal junction define Siewert classification . 3 . Patients gastroesophageal junction tumor eligible : AEG Type I : Adenocarcinoma distal esophagus usually arise area specialize intestinal metaplasia esophagus ( eg , Barrett 's esophagus , may infiltrate esophagogastric junction ) . AEG Type II : True carcinoma cardia arise cardiac epithelium short segment intestinal metaplasia esophagogastric junction . 4 . Patients gastroesophageal junction tumor NOT eligible : AEG Type III : Subcardial gastric carcinoma infiltrates esophagogastric junction distal esophagus . 2 . Patients must least one paraffin block available ( least 15 unstained slide analysis tumor EGFR status . 1 . Patients history esophageal GE junction carcinoma treat surgical resection develop radiological clinical evidence metastatic cancer require separate histological cytological confirmation metastatic disease unless interval great five year elapse primary surgery development metastatic disease OR primary cancer stage I . 2 . Clinicians consider biopsy lesion establish diagnosis metastatic esophageal GE junction carcinoma substantial clinical ambiguity regard nature source apparent metastasis . 3 . Patients Measurable Disease Lesions accurately measure least one dimension ( long diameter record ) ≥ 20 mm conventional technique ≥ 10 mm spiral CT scan . 4 . Prior Treatment : 1 . No prior chemotherapy radiotherapy . No prior therapy specifically directly target EGF ( R ) pathway . 2 . No prior allergic reaction chimerized murine monoclonal antibody therapy document presence human antimouse antibody ( HAMA ) . 3 . Patients must complete major surgery ≥ 4 week minor surgery ≥ 2 week registration . Patients must fully recovered procedure . Insertion vascular access device consider major minor surgery . 4 . No concurrent use investigational agent allow participate study . 5 . Patient Characteristics : 1 . ECOG Performance Status 02 2 . ≥ 18 year age 3 . Patients must document stable weight ( le one pound weight loss ) least one week prior registration . 4 . Nonpregnant breastfeeding . The effect cetuximab , cisplatin , epirubicin , fluorouracil , leucovorin , irinotecan , oxaliplatin develop human fetus wellknown . Because risk toxicity nursing infant secondary cetuximab , cisplatin , epirubicin , fluorouracil , irinotecan , oxaliplatin treatment mother unknown may harmful , breastfeed must discontinue . 6 . No myocardial infarction &lt; 6 month prior registration New York Heart Association classification III IV . 7 . No ≥ grade 2 diarrhea within 7 day prior registration . 8 . Patients may concurrently follow condition : 1 . Known central nervous system metastases carcinomatous meningitis 2 . Interstitial pneumonia symptomatic interstitial fibrosis lung 3 . Seizure disorder active neurological disease require antiepileptic medication 4 . ≥ grade 2 peripheral neuropathy 9 . No evidence Gilbert 's Syndrome Patients Gilbert 's Syndrome may great risk irinotecan toxicity due abnormal glucuronidation SN38 , active metabolite irinotecan . Evidence Gilbert 's Syndrome would include documentation elevation indirect bilirubin time patient 's medical history . 10 . Required Initial Laboratory Data : 1 . Granulocytes ≥ 1500/µl 2 . Platelet count ≥ 100,000/µl 3 . Creatinine ≤ 1.5 mg/dL 4 . AST ( SGOT ) ≤ 5.0 x Upper limit normal 5 . Total bilirubin ≤ 1.5 mg/dL 6 . Albumin ≥ 2.5 grams/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
</DOC>